COMPANY

Cellenkos

HQ: Houston, TX source · cellenkosinc.com ↗

Cellenkos is a Clinical-Stage Biotechnology Company that is developing Allogeneic, Tissue-Targeted, Immune T-Regulatory Cell Therapies to Treat Autoimmune Diseases & Inflammatory Disorders. We are a patient-centric, clinical stage, allogeneic T regulatory cell therapy biotechnology team focused on treating Rare Inflammatory Diseases. From company website Source · Oct 13, 2026

Keywords: cell therapies clinical-stage biotechnology cell therapy Steroid Refractory Graft Versus Host Disease Aplastic Anemia Bone Marrow Disease Myelofibrosis Amyotrophic Lateral Sclerosis Guillain-Barré Syndrome COVID19 ARDS CK0801 CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched) CK0804 CK0803 CK0802

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Timeline

Aug 3, 2026 Trial start Phase 2: CK0801 for Treatment of Aplastic Anemia source ↗
Jul 1, 2026 Trial start Phase 1/Phase 2: CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD) source ↗
Apr 3, 2023 Trial start Phase 1: Regulatory T Cells for Amyotrophic Lateral Sclerosis source ↗
Dec 27, 2022 Trial start Phase 1: Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs source ↗
2022-11 Trial start Phase 1: A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS) source ↗
Sep 29, 2020 Trial start Phase 1: REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia source ↗
May 30, 2019 Trial start Phase 1: A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF) source ↗

Upcoming milestones

May 25, 2027 (ESTIMATED) · Phase 1 · A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF) · NCT03773393
Jun 30, 2028 (ESTIMATED) · Phase 1/Phase 2 · CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD) · NCT07576699
Aug 3, 2028 (ESTIMATED) · Phase 2 · CK0801 for Treatment of Aplastic Anemia · NCT07499102

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT07576699	CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)	Phase 1/Phase 2	Not yet recruiting	Jul 1, 2026	Jun 30, 2028 (estimated)
NCT07499102	CK0801 for Treatment of Aplastic Anemia	Phase 2	Not yet recruiting	Aug 3, 2026	Aug 3, 2028 (estimated)
NCT03773393	A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)	Phase 1	Active, not recruiting	May 30, 2019	May 25, 2027 (estimated)
NCT05423691	Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs	Phase 1	Recruiting	Dec 27, 2022	Apr 30, 2026 (estimated)
NCT05695521	Regulatory T Cells for Amyotrophic Lateral Sclerosis	Phase 1	Active, not recruiting	Apr 3, 2023	2026-05 (estimated)
NCT03773328	A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)	Phase 1	Withdrawn	2022-11	2025-02 (estimated)
NCT04468971	REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia	Phase 1	Completed	Sep 29, 2020	Oct 22, 2021 (actual)

Connect

Contact page